tiprankstipranks
Advertisement
Advertisement
Oric Pharmaceuticals price target lowered to $17 from $20 at Wedbush
PremiumThe FlyOric Pharmaceuticals price target lowered to $17 from $20 at Wedbush
18d ago
Oric’s rinzi efficacy ‘comparable’ to Pfizer’s mevro, says Cantor Fitzgerald
Premium
The Fly
Oric’s rinzi efficacy ‘comparable’ to Pfizer’s mevro, says Cantor Fitzgerald
18d ago
Oric selloff on cancer data ‘appears exaggerated,’ says JonesResearch
Premium
The Fly
Oric selloff on cancer data ‘appears exaggerated,’ says JonesResearch
18d ago
Oric selloff brings favorable entry point, says H.C. Wainwright
PremiumThe FlyOric selloff brings favorable entry point, says H.C. Wainwright
1M ago
Oric Pharmaceuticals reports Q4 revenue C$17.39M vs. C$18.04M last year
Premium
The Fly
Oric Pharmaceuticals reports Q4 revenue C$17.39M vs. C$18.04M last year
1M ago
Constructive Buy Thesis on ORIC Driven by Differentiated PRC2 Biology and Manageable Safety Profile for Rinzimetostat
Premium
Ratings
Constructive Buy Thesis on ORIC Driven by Differentiated PRC2 Biology and Manageable Safety Profile for Rinzimetostat
1M ago
ORIC Pharmaceuticals: Differentiated PRC2 Inhibitor Rinzimetostat Mitigates Sector Safety Overhang and Supports Buy Rating
PremiumRatingsORIC Pharmaceuticals: Differentiated PRC2 Inhibitor Rinzimetostat Mitigates Sector Safety Overhang and Supports Buy Rating
1M ago
Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright
Premium
The Fly
Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright
2M ago
Oric Pharmaceuticals price target raised to $17 from $16 at Citi
Premium
The Fly
Oric Pharmaceuticals price target raised to $17 from $16 at Citi
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100